SCHEMBL3295305

SCHEMBL3295305

CCC(C)NC(=O)/C=C/C(=O)OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.50
KEAP1 Q14145 1/20 0.50
NFE2L2 Q16236 1/20 0.50
TAS1R3 Q7RTX0 2/20 0.48
TAS1R1 Q7RTX1 2/20 0.48
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP3 P08254 1/20 0.46
GFPT1 Q06210 1/20 0.45
PTGS2 P35354 1/20 0.40
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
MAPK1 P28482 1/20 0.38
CA2 P00918 3/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
STAT3 P40763 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3295309 1.00 HCAR2 (0.50) HCAR2KEAP1NFE2L2TAS1R3TAS1R1
SCHEMBL13296122 1.00 HCAR2 (0.50) HCAR2KEAP1NFE2L2TAS1R3TAS1R1
SCHEMBL3294574 0.80 ALDH1A1 (0.63) HCAR2TAS1R3TAS1R1MMP1MMP2
SCHEMBL13296121 0.80 ALDH1A1 (0.63) HCAR2TAS1R3TAS1R1MMP1MMP2
SCHEMBL3294577 0.80 ALDH1A1 (0.63) HCAR2TAS1R3TAS1R1MMP1MMP2
SCHEMBL13296114 0.79 HCAR2 (0.43) HCAR2KEAP1NFE2L2TAS1R3TAS1R1
SCHEMBL21559558 0.78 TAS1R3 (0.45) TAS1R3TAS1R1MMP1MMP2MMP3
SCHEMBL20450459 0.78 TAS1R3 (0.47) TAS1R3TAS1R1MMP1MMP2MMP3
SCHEMBL23470216 0.78 TAS1R3 (0.43) TAS1R3TAS1R1MMP1MMP2MMP3
SCHEMBL17688555 0.74 HCAR2 (0.52) HCAR2KEAP1NFE2L2GFPT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732018-B2 Durable coating compositions containing novel aspartic amine compounds E. I. DU PONT DE NEMOURS AND COMPANY (US) 2010-06-08 US disclosed
EP-1833783-B1 DURABLE COATING COMPOSITIONS CONTAINING NOVEL ASPARTIC AMINE COMPOUNDS DU PONT (US) 2009-04-15 EP disclosed
US-7449242-B2 Durable coating compositions containing novel aspartic amine compounds E.I. DU PONT DE NEMOURS & COMPANY (US) 2008-11-11 US disclosed
EP-1833783-A1 DURABLE COATING COMPOSITIONS CONTAINING NOVEL ASPARTIC AMINE COMPOUNDS E.I. DUPONT DE NEMOURS AND COMPANY (US) 2007-09-19 EP disclosed
US-7166748-B2 Durable coating compositions containing novel aspartic amine compounds E.I. DUPONT DE NEMOURS & CO. (US) 2007-01-23 US disclosed
US-20060228563-A1 Durable coating compositions containing novel aspartic amine compounds AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2006-10-12 US disclosed
US-20060155056-A1 Durable coating compositions containing novel aspartic amine compunds AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2006-07-13 US disclosed
US-20060155149-A1 Durable coating compositions containing novel aspartic amine compounds AXALTA COATING SYSTEMS IP CO. LLC (FORMERLY KNOWN AS U.S. COATINGS IP CO. LLC) 2006-07-13 US disclosed
WO-2006066031-A1 DURABLE COATING COMPOSITIONS CONTAINING NOVEL ASPARTIC AMINE COMPOUNDS E. I. DU PONT DE NEMOURS AND COMPANY (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060155149-A1 Durable coating compositions containing novel aspartic amine compounds H1-10, H1-0, H1-5 HCAR2 1539/4885KEAP1 2790/4885NFE2L2 4756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.